Meqsel Tablet is a prescription medication containing the active ingredient Trametinib, which belongs to a class of drugs known as MEK inhibitors. It is primarily used in the treatment of certain types of cancer, particularly unresectable or metastatic melanoma—a form of skin cancer that cannot be surgically removed or has spread to other parts of the body. Additionally, Meqsel is utilized in combination with other medications to treat non-small cell lung cancer (NSCLC) and anaplastic thyroid cancer that exhibit specific genetic mutations. Meqsel (Trametinib) is a targeted therapy that plays a significant role in managing specific types of cancer by inhibiting the MEK pathway, thereby reducing cancer cell growth and proliferation.

Mechanism of Action:

Trametinib targets and inhibits the activity of the MEK1 and MEK2 proteins, which are components of the mitogen-activated protein kinase (MAPK) pathway. This pathway is involved in regulating cell growth and division. By blocking MEK1 and MEK2, Trametinib helps prevent the proliferation of cancer cells and slows tumor growth.

Administration:

Meqsel is available in tablet form and should be taken orally. The recommended dosage and duration of treatment depend on the specific condition being treated and the patient's overall health. It is essential to follow the prescribing physician's instructions carefully. Typically, the tablet should be swallowed whole with a full glass of water and can be taken with or without food. Patients are advised not to crush, chew, or break the tablet. If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose; in such cases, the missed dose should be skipped to avoid doubling up.

Common Side Effects:

Patients undergoing treatment with Meqsel may experience several side effects. Commonly reported ones include:

Skin-related issues:

• Rash
• Dry skin
• Itching
• Acne

Gastrointestinal symptoms:

• Diarrhea
• Nausea
• Vomiting
• Abdominal pain

General discomfort:

• Fatigue
• Fever
• Chills

Edema:

• Swelling of the limbs (peripheral edema)
• Lymphedema (swelling due to lymph fluid)

Other symptoms:

• Headache
• Cough
• Joint pain
• Night sweats
• Decreased appetite
• Constipation
• Muscle pain

While many side effects are manageable, patients should promptly report any persistent or severe symptoms to their healthcare provider.

Serious Side Effects:

Although less common, Meqsel can cause serious side effects that require immediate medical attention:

• Cardiac issues: Heart failure, irregular heartbeat, or shortness of breath.

• Ocular problems: Blurred vision, vision changes, or eye pain, which may indicate retinal detachment.

• Liver injury: Symptoms such as yellowing of the skin or eyes (jaundice), dark urine, or severe abdominal pain.

• Severe skin reactions: Development of painful rashes, blisters, or peeling skin, which could signify conditions like Stevens-Johnson syndrome.

• Bleeding: Unusual bleeding or bruising, blood in stools or urine, or coughing up blood.

If any of these serious side effects occur, it is crucial to seek immediate medical attention.

Precautions:

Before initiating treatment with Meqsel, patients should inform their healthcare provider about any existing medical conditions, especially:

• Liver or kidney problems: Dose adjustments may be necessary.

• Heart conditions: Monitoring may be required due to potential cardiac side effects.

• Eye disorders: Regular eye examinations are recommended during treatment.

• Bleeding disorders: Caution is advised as the medication may increase bleeding risk.

Additionally, patients should disclose all medications they are currently taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements, as certain substances may interact with Trametinib, affecting its efficacy or increasing the risk of adverse effects.

Use in Specific Populations:

• Pregnancy: Meqsel can cause fetal harm and is not recommended for use during pregnancy. Women of childbearing potential should use effective contraception during treatment and for at least 4 months after the last dose.

• Breastfeeding: It is unknown whether Trametinib passes into breast milk. Due to potential risks to the infant, breastfeeding is not recommended during treatment and for at least 4 months after the final dose.

Storage:

Meqsel tablets should be stored in a refrigerator at temperatures between 2°C to 8°C (36°F to 46°F) and protected from light and moisture. Do not freeze the medication. Keep the tablets in their original packaging until use and ensure they are out of reach of children and pets.